RecruitingNot Applicable

SSM Predicts Outcomes of CLD Inpatients With Acute Liver Injury

China411 participantsStarted 2024-01-01

Plain-language summary

In this study, a single non-invasive tool, spleen stiffness measurement (SSM), was used to monitor the disease regression of inpatients with chronic liver disease (CLD) and acute liver injury. The present study aimed to establish an early diagnosis warning model for acute-on-chronic liver failure (ACLF) by SSM and investigate the effect of dynamic changes in SSM on the short-term prognosis (28-day, 90-day morbidity and mortality) of inpatients with CLD and acute liver injury.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age between 18 years and 80 years
✓. Chronic liver diseases regardless of etiology
✓. Acute liver injury with total bilirubin ≥ 3 mg/dl regardless of inducement

Exclusion criteria

✕. Prior surgery of liver diseases before enrollment such as liver transplantation, transjugular intrahepatic portosystemic shunt (TIPS), splenectomy and partial splenic embolization
✕. Severe extrahepatic diseases such as chronic obstructive pulmonary disease level IV, chronic kidney disease with end-stage renal failure, myocardial infarction within 3 months before admission
✕. Receiving Immunosuppressive drugs for reasons rather than chronic liver diseases
✕. Diagnosis of hepatocellular carcinoma or other non-liver malignancies during screening period
✕. Serious mental illnesses such as anxiety, depressive disorders to obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD)
✕. The pregnant
✕. Jaundice due to biliary obstruction or cholestasis
✕. Unsuitable to participate in this study judging by investigators

What they're measuring

90-day transplant-free mortality

Timeframe: Day 90

Trial details

NCT IDNCT06173947

SponsorNanfang Hospital, Southern Medical University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-09-30

Contact for this trial

Jinjun Chen, PHD

86-18588531001 chjj@smu.edu.cn

View on ClinicalTrials.gov More End Stage Liver Disease trials